ZA201702377B - Quinoline carboxamides for use in the treatment of multiple myeloma - Google Patents
Quinoline carboxamides for use in the treatment of multiple myelomaInfo
- Publication number
- ZA201702377B ZA201702377B ZA2017/02377A ZA201702377A ZA201702377B ZA 201702377 B ZA201702377 B ZA 201702377B ZA 2017/02377 A ZA2017/02377 A ZA 2017/02377A ZA 201702377 A ZA201702377 A ZA 201702377A ZA 201702377 B ZA201702377 B ZA 201702377B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- multiple myeloma
- quinoline carboxamides
- carboxamides
- quinoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185892 | 2014-09-23 | ||
| PCT/EP2015/071391 WO2016042112A1 (en) | 2014-09-23 | 2015-09-18 | Quinoline carboxamides for use in the treatment of multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201702377B true ZA201702377B (en) | 2018-08-29 |
Family
ID=51660309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/02377A ZA201702377B (en) | 2014-09-23 | 2017-04-04 | Quinoline carboxamides for use in the treatment of multiple myeloma |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9956212B2 (enExample) |
| EP (1) | EP3041472B1 (enExample) |
| JP (1) | JP6647287B2 (enExample) |
| KR (1) | KR102533033B1 (enExample) |
| CN (1) | CN107108510B (enExample) |
| AU (1) | AU2015316824B2 (enExample) |
| CA (1) | CA2961978C (enExample) |
| EA (1) | EA030948B1 (enExample) |
| ES (1) | ES2631194T3 (enExample) |
| IL (1) | IL251043B (enExample) |
| MX (1) | MX366837B (enExample) |
| NZ (1) | NZ730816A (enExample) |
| PL (1) | PL3041472T3 (enExample) |
| WO (1) | WO2016042112A1 (enExample) |
| ZA (1) | ZA201702377B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX366837B (es) * | 2014-09-23 | 2019-07-26 | Active Biotech Ab | Quinolinas carboxamidas para usarse en el tratamiento de mielomas multiples. |
| ES3032708T3 (en) * | 2020-03-03 | 2025-07-23 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
| MX2023000903A (es) | 2020-07-23 | 2023-04-20 | Univ Erasmus Med Ct Rotterdam | Proteinas s100 como nuevos objetivos terapeuticos en neoplasias mieloproliferativas. |
| KR20230133317A (ko) | 2021-01-18 | 2023-09-19 | 액티브 바이오테크 에이비 | 골수이형성 증후군의 치료에 이용하기 위한 타스퀴니모드또는 이의 약제학적으로 허용가능한 염 |
| AU2022281056A1 (en) | 2021-05-25 | 2023-11-30 | Active Biotech Ab | A plurality of tasquinimod particles and use thereof |
| CA3221689A1 (en) | 2021-07-02 | 2023-01-05 | Hans Wannman | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| US6395750B1 (en) * | 1999-10-25 | 2002-05-28 | Active Biotech Ab | Drugs for the treatment of malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| KR20130043104A (ko) * | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
| SG186430A1 (en) | 2010-07-09 | 2013-01-30 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
| US20140148350A1 (en) * | 2010-08-18 | 2014-05-29 | David Spetzler | Circulating biomarkers for disease |
| WO2012034543A1 (es) | 2010-09-13 | 2012-03-22 | Universidad De Costa Rica | Conector estructural para bambú |
| FR2967353B1 (fr) * | 2010-11-16 | 2013-08-16 | Centre Nat Rech Scient | Derives de quinolinone |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| MX366837B (es) * | 2014-09-23 | 2019-07-26 | Active Biotech Ab | Quinolinas carboxamidas para usarse en el tratamiento de mielomas multiples. |
-
2015
- 2015-09-18 MX MX2017003294A patent/MX366837B/es active IP Right Grant
- 2015-09-18 PL PL15763622T patent/PL3041472T3/pl unknown
- 2015-09-18 JP JP2017513751A patent/JP6647287B2/ja active Active
- 2015-09-18 ES ES15763622.6T patent/ES2631194T3/es active Active
- 2015-09-18 WO PCT/EP2015/071391 patent/WO2016042112A1/en not_active Ceased
- 2015-09-18 EA EA201790687A patent/EA030948B1/ru not_active IP Right Cessation
- 2015-09-18 EP EP15763622.6A patent/EP3041472B1/en active Active
- 2015-09-18 US US15/510,728 patent/US9956212B2/en active Active
- 2015-09-18 KR KR1020177010510A patent/KR102533033B1/ko active Active
- 2015-09-18 AU AU2015316824A patent/AU2015316824B2/en active Active
- 2015-09-18 CA CA2961978A patent/CA2961978C/en active Active
- 2015-09-18 CN CN201580051397.XA patent/CN107108510B/zh active Active
- 2015-09-18 NZ NZ730816A patent/NZ730816A/en unknown
-
2017
- 2017-03-09 IL IL251043A patent/IL251043B/en active IP Right Grant
- 2017-04-04 ZA ZA2017/02377A patent/ZA201702377B/en unknown
-
2018
- 2018-04-06 US US15/947,279 patent/US10314836B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017528473A (ja) | 2017-09-28 |
| US10314836B2 (en) | 2019-06-11 |
| JP6647287B2 (ja) | 2020-02-14 |
| EA030948B1 (ru) | 2018-10-31 |
| CN107108510B (zh) | 2020-10-23 |
| AU2015316824A1 (en) | 2017-04-27 |
| CA2961978C (en) | 2023-03-14 |
| IL251043A0 (en) | 2017-04-30 |
| AU2015316824B2 (en) | 2020-10-29 |
| ES2631194T3 (es) | 2017-08-29 |
| MX366837B (es) | 2019-07-26 |
| WO2016042112A1 (en) | 2016-03-24 |
| CA2961978A1 (en) | 2016-03-24 |
| CN107108510A (zh) | 2017-08-29 |
| US20170273967A1 (en) | 2017-09-28 |
| EA201790687A1 (ru) | 2017-08-31 |
| EP3041472B1 (en) | 2017-02-01 |
| KR20170052691A (ko) | 2017-05-12 |
| IL251043B (en) | 2020-02-27 |
| EP3041472A1 (en) | 2016-07-13 |
| US9956212B2 (en) | 2018-05-01 |
| PL3041472T3 (pl) | 2017-08-31 |
| US20180228794A1 (en) | 2018-08-16 |
| BR112017004947A2 (pt) | 2017-12-05 |
| NZ730816A (en) | 2022-01-28 |
| KR102533033B1 (ko) | 2023-05-15 |
| MX2017003294A (es) | 2017-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL249481A0 (en) | Difluoromethyl-indanyl-nicotinic carboxamides | |
| HUE061672T2 (hu) | Glikán-interakcióban lévõ vegyületek és felhasználási módszerek | |
| IL248856A0 (en) | New treatment | |
| SI3089971T1 (sl) | Spojine in postopki za uporabo | |
| HUE051924T2 (hu) | Hõkezelési eljárás | |
| GB201401430D0 (en) | Treatment process | |
| PL3215157T3 (pl) | Apilimod do stosowania w leczeniu czerniaka | |
| ZA201702377B (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| IL252174B (en) | Quinoline carboxamides for use in the treatment of leukemia | |
| GB201416832D0 (en) | Methods of treatment | |
| SG11201702700UA (en) | Methods for the treatment of peri-implantitis | |
| IL252707B (en) | Compositions and methods for treating diseases | |
| GB201411027D0 (en) | Treatment | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201400311D0 (en) | Treating Susceptibility | |
| GB201412411D0 (en) | Treatment | |
| GB201418541D0 (en) | Materials for use with general hyperthermia treatment | |
| GB201403697D0 (en) | Compounds and methods of use | |
| GB201417719D0 (en) | New treatment | |
| GB201408384D0 (en) | New treatment | |
| GB201413317D0 (en) | Atheroscierosis treatment | |
| GB201412410D0 (en) | Treatment | |
| GB201400235D0 (en) | Treatment | |
| GB201400241D0 (en) | Treatment | |
| GB201400240D0 (en) | Treatment |